GENESEEQ, Author at Geneseeq Technology Inc. | A Precision Oncology Company

August 26, 2026

Beyond Mutation-Only MRD: Making Better Use of ctDNA Data

0 Comments10 Minutes

August 11, 2026

Geneseeq Expands PanTRKare™ with a Third NMPA-Approved CDx Application for VELMARTO® (Eratrectinib)

0 Comments4 Minutes

November 10, 2025

Geneseeq Receives NMPA Approval for PanTRKare™ – China’s First NGS-Based Pan-Solid Tumor Companion Diagnostic Kit for NTRK Gene Fusions

0 Comments4 Minutes

September 29, 2025

Geneseeq Validates Cell-free DNA Blood Test for Early Detection of Pancreatic Cancer in a Prospective Study

0 Comments3 Minutes

September 2, 2025

GeneseeqPrime® Gains FDA 510(k) Clearance

0 Comments3 Minutes

May 28, 2025

Geneseeq’s Breakthrough Cancer Detection Blood Test Published in Nature Medicine

0 Comments4 Minutes

May 21, 2025

Geneseeq Showcases Cutting-Edge Liquid Biopsy Research Across Multiple Cancer Types at ASCO 2025

0 Comments4 Minutes

May 7, 2025

Geneseeq Unveils Groundbreaking Blood Test for Early Detection of Pancreatic Cancer

0 Comments4 Minutes

April 9, 2025

Geneseeq Technology Inc. to showcase seventeen studies at 2025 American Association for Cancer Research (AACR) annual meeting

0 Comments3 Minutes

December 3, 2024

GENESEEQ’S NGS LIQUID BIOPSY KIT MARKS THE FIRST TO ENTER NMPA’S SPECIAL REVIEW AND APPROVAL OF INNOVATIVE MEDICAL DEVICE

0 Comments2 Minutes